Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

272
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
272
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

473
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
473
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

168
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
168
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

415
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
415
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

294
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
294
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

470
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
470

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same author

Asynchronous Electronic Screening for Unhealthy Alcohol Use Among Veterans in Primary Care: A Cluster Randomized Quality Improvement Trial.

JAMA internal medicine·2026
Same authorSame journal

Frailty Predicts Incident Osteoporotic Fractures in Veterans with Rheumatoid Arthritis.

Arthritis care & research·2026
Same author

Reply.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study.

Journal for immunotherapy of cancer·2026
Same author

Adult-onset STING-associated vasculopathy.

Journal of human immunity·2026
Same journal

Associations Between Social Risk Factors and Acute Care Use Among Patients with Rheumatic Conditions.

Arthritis care & research·2026
Same journal

Engagement Patterns with an AI Health Coach for Systemic Sclerosis Self-Management: A Mixed Methods Study.

Arthritis care & research·2026
Same journal

Anorectal Dysfunction in Systemic Sclerosis: Clinical Phenotypes and Functional Patterns.

Arthritis care & research·2026
Same journal

Determinants of body mass index in early systemic sclerosis: implications for nutritional risk stratification.

Arthritis care & research·2026
Same journal

Assessing Reliability of an Electronic Gout Flare Assessment Protocol.

Arthritis care & research·2026
See all related articles

Related Experiment Video

Updated: Jan 11, 2026

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
07:44

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass

Published on: July 14, 2023

1.6K

Mortality in US Veterans With Rheumatoid Arthritis Treated With Immune Checkpoint Inhibitors.

Madeline L O'Sullivan1, Grant W Cannon1, Brian C Sauer1

  • 1Salt Lake City VA and University of Utah.

Arthritis Care & Research
|November 10, 2025
PubMed
Summary
This summary is machine-generated.

Patients with rheumatoid arthritis (RA) receiving immune checkpoint inhibitors (ICIs) for cancer treatment showed no increased mortality compared to those without RA. These findings suggest ICIs are a viable option for RA patients undergoing cancer therapy.

More Related Videos

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.0K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.3K

Related Experiment Videos

Last Updated: Jan 11, 2026

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
07:44

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass

Published on: July 14, 2023

1.6K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.0K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.3K

Area of Science:

  • Oncology
  • Rheumatology
  • Immunology

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease.
  • Immune checkpoint inhibitors (ICIs) are a class of cancer immunotherapy drugs.
  • The safety and efficacy of ICIs in RA patients are not fully understood.

Purpose of the Study:

  • To compare all-cause and cause-specific mortality in RA patients versus non-RA patients treated with ICIs.
  • To evaluate the impact of RA on survival outcomes following ICI cancer treatment.

Main Methods:

  • Retrospective cohort study within the Veterans Health Administration (VHA).
  • Identified RA patients and matched non-RA controls who received ICIs.
  • Analyzed mortality data using Cox models, Kaplan-Meier curves, and log-rank testing.

Main Results:

  • 301 RA patients and 2,114 non-RA controls were included.
  • No significant difference in all-cause mortality between RA and non-RA groups (adjusted HR 1.09; 95% CI 0.94-1.25).
  • Neoplasm was the most common cause of death in both groups; deaths from infection were rare.

Conclusions:

  • RA patients treated with ICIs did not have increased mortality or different causes of death compared to non-RA patients.
  • ICI therapy may be a safe treatment option for cancer in RA patients.
  • Further research is warranted to confirm these findings.